ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of TDF+3TC+EFV in Adults With HIV/HBV Coinfection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01751555
Recruitment Status : Completed
First Posted : December 18, 2012
Last Update Posted : June 28, 2013
Sponsor:
Collaborator:
Gilead Sciences
Information provided by (Responsible Party):
National Center for AIDS/STD Control and Prevention, China CDC

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : June 2013
  Actual Study Completion Date : June 2013
Publications:
G Matthews, A Avihingsanon, S Lewin, and others. Tenofovir-based Highly Active Antiretroviral Therapy (HAART) is associated with high rates of HBV DNA suppression and HBeAg seroconversion in Thai HIV-HBV coinfected patients. 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2008). San Francisco. October 31-November 4, 2008. Abstract 907. O Lada, A Gervais, M Branger, and others. De Novo Combination Therapy of Tenofovir Disoproxil Fumarate (TDF) Plus Lamivudine (LAM) or TDF Plus Emtricitabine (FTC) Is Associated With Early Virologic Response in HIV/HBV Co-Infected Patients. 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2008). San Francisco. October 31-November 4, 2008. Abstract 922.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):